Theraclone inks $18M antibody pact

Theraclone Sciences has struck a development deal worth up to $18 million with Japan's Zenyaku Kogyo. Theraclone will pocket an unspecified portion of that as an upfront payment for the alliance, which will focus on identifying antibodies that could be used to fight future pandemics. The deal comes just weeks after the Seattle-based biotech company revealed the discovery of two antibodies that can be used to fight HIV. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.